FibroBiologics Inc. (NASDAQ:FBLG) on Monday released the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).



<h2>FibroBiologics Advances CYWC628 Toward Clinical Testing In DFUs</h2>



The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration's current Good Manufacturing Practices (cGMP) and has passed all required safety and quality testing, enabling its release for clinical use.



The milestone follows the company's recent completion of manufacturing the first cGMP batch of CYWC628.



FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for chronic diseases.



CYWC628 is an investigational fibroblast-based therapy designed to address DFUs.



<div>




Read Also:

EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy




</div>


<h2>Company Prepares For Patient Enrollment</h2>



The Phase 1/2 clinical trial is evaluating the safety, tolerability, and preliminary efficacy of CYWC628 in patients with DFUs.



Interim results from the study are expected in the third quarter of 2026, with complete and primary safety and efficacy results reported by the end of 2026. 



&#34;With the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1/2 DFU trial,&#34; said Pete O'Heeron, Founder and CEO of FibroBiologics.



In April, FibroBiologics raised $3 million via 2.27 million shares and warrants to purchase up to 2.272 million shares at a combined price of $1.32. The Warrants have an exercise price of $1.32 per share.



<h2>Patent Filing Expands Platform Protection</h2>



In December 2025, FibroBiologics submitted a new patent application with the U.S. Patent and Trademark Office (USPTO).



The patent application covers a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration.



The application, if granted, strengthens the protection for the company's fibroblast technology that leverages fibroblast cells, spheroids, and/or fibroblast-differentiated chondrocyte spheroids to support structural and functional repair in orthopedic tissues.



FBLG Price Action: FibroBiologics shares were down 4.79% at $1.39 during premarket trading on Monday, according to Benzinga Pro. Over the past month, FBLG has gained about 2.2% versus a 9.9% rise in the S&amp;P 500 and is down roughly 71% year-to-date compared to the index's 5.1% gain.



Image via Shutterstock

FBLG

LABU

SBIO

FibroBiologics Inc. has released the first batch of its CYWC628 drug product for a Phase 1/2 clinical trial targeting diabetic foot ulcers (DFUs). The product has passed cGMP checks, allowing patient enrollment to begin, with interim data expected in Q3 2026. The company recently raised $3 million and filed a new patent application to protect its fibroblast-derived therapy platform. Despite a recent decline in stock price, FibroBiologics continues to advance its clinical testing efforts.

benzinga_article

Fibrobiologics

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

S&P 500

EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study